CN Patent

CN104138370A — 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂

Assigned to Boehringer Ingelheim International GmbH · Expires 2014-11-12 · 12y expired

What this patent protects

本发明涉及使用SGLT-2抑制剂治疗或预防一种或多种选自I型糖尿病、II型糖尿病、葡萄糖耐量降低及高血糖症的病症。此外，本发明涉及一种预防或治疗代谢障碍及相关病症的方法。

USPTO Abstract

本发明涉及使用SGLT-2抑制剂治疗或预防一种或多种选自I型糖尿病、II型糖尿病、葡萄糖耐量降低及高血糖症的病症。此外，本发明涉及一种预防或治疗代谢障碍及相关病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104138370A
Jurisdiction
CN
Classification
—
Expires
2014-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.